Work

Supplementary Data from Phase II Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Metastatic Melanoma

Year: 2023

Type: supplementary-materials

Abstract: Supplementary Data from Phase II Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Metastatic Melanoma

DOI: 10.1158/1078-0432.22439629.v1

Authors: David B. Solit, Iman Osman, David Polsky, Katherine S. Panageas, Adil Daud, James S. Goydos, Jerrold Teitcher, Jedd D. Wolchok, F. Joseph Germino, Susan E. Krown, Daniel Coit, Neal Rosen, Paul B. Chapman

Language: English

Topic: Melanoma and MAPK Pathways

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4362431328

Cites:

Cited by:

Related to: 10